By Nana O 
In a significant advancement for individuals living with spinal cord injuries, researchers at The University of Texas at Dallas (UT Dallas) have demonstrated unprecedented rates of recovery in arm and hand function. A new clinical study, published in the prestigious journal Nature on May 21, details a novel therapeutic approach that combines the stimulation of a nerve in the neck with progressive, individualized rehabilitation. This innovative method, termed closed-loop vagus nerve stimulation (CLV), has yielded meaningful functional improvements in participants with incomplete spinal cord injuries, offering a beacon of hope for a population with limited treatment options.
The remarkable outcomes of this study position the UT Dallas scientists at the cusp of a pivotal trial, a critical step in their journey toward potential Food and Drug Administration (FDA) approval for vagus nerve stimulation as a treatment for upper-limb impairment stemming from spinal cord injuries. This breakthrough is the culmination of over a decade of dedicated research in neuroscience and bioengineering by investigators at UT Dallas, building upon prior successes in applying CLV to stroke recovery.
The Science Behind Closed-Loop Vagus Nerve Stimulation
The CLV therapy employs a sophisticated system where electrical pulses are delivered to the brain via a miniaturized device implanted in the neck. Crucially, these pulses are precisely timed to coincide with rehabilitative exercises, creating a synergistic effect. The vagus nerve, a cranial nerve that plays a role in various bodily functions including motor control and sensory processing, is believed to be a key pathway for this therapeutic intervention.
Previous research conducted by UT Dallas had already established the efficacy of stimulating the vagus nerve during physical therapy for patients recovering from stroke. This prior work demonstrated the therapy’s capacity to promote neuroplasticity, essentially rewiring damaged areas of the brain and leading to enhanced functional recovery. However, the application of CLV to spinal cord injuries presented a unique challenge, as Dr. Michael Kilgard, the Margaret Fonde Jonsson Professor of Neuroscience in the School of Behavioral and Brain Sciences and corresponding author of the study, explained.
"In stroke, people who do only therapy may get better, and adding CLV multiplies that improvement," Dr. Kilgard stated. "This study is different: Therapy alone for spinal cord injury didn’t help our participants at all." This stark contrast highlights the distinct nature of spinal cord injury and underscores the transformative potential of CLV in addressing its specific deficits.
A Rigorous Clinical Trial Design and Its Outcomes
The clinical trial involved 19 participants who had sustained chronic, incomplete cervical spinal cord injuries. These individuals underwent a rigorous 12-week rehabilitation program that incorporated simple video games designed to elicit specific upper-limb movements. The CLV implant was activated only upon successful completion of these movements, thereby reinforcing the neural pathways responsible for voluntary control.
The results were compelling: participants experienced significant improvements in arm and hand strength. Beyond mere strength gains, the therapy also led to enhancements in speed, range of motion, and overall hand function, directly translating into simplified daily living activities.
"These activities allow patients to regain strength, speed, range of motion and hand function. They simplify daily living," commented Dr. Robert Rennaker, professor of Neuroscience and the Texas Instruments Distinguished Chair in Bioengineering, who was instrumental in designing the miniature implanted CLV device.
The study was designed as a combined Phase 1 and Phase 2 clinical trial, incorporating a randomized placebo control in its initial phase. Nine of the 19 participants received sham stimulation for the first 18 therapy sessions, while the remaining participants received active CLV treatment. Following this initial period, all participants then received CLV for the subsequent 18 sessions, allowing for a comprehensive evaluation of the therapy’s effects.
A notable aspect of the study was its broad applicability. Participants ranged in age from 21 to 65 years, and their time since injury varied from one to 45 years. Crucially, neither age nor the duration of the injury, nor the severity of residual hand movement, influenced the degree of positive response to the treatment.
Dr. Jane Wigginton, a study co-author and Chief Medical Officer at TxBDC, elaborated on this finding: "This approach produces results regardless of these factors, which often cause significant differences in success rates of other types of treatment." Dr. Wigginton, who also co-directs UTD’s Clinical and Translational Research Center and serves as medical science research director at the Center for BrainHealth, was responsible for planning the clinical interactions and ensuring patient protections throughout the trial. Her perspective emphasizes the remarkable medical significance of a therapy that transcends common barriers to treatment success. "It is remarkable from a medical standpoint," she remarked.
A Decade of Innovation and Future Prospects
The Texas Biomedical Device Center (TxBDC) has dedicated 13 years to researching and developing CLV for a wide spectrum of medical conditions. This sustained effort has already led to FDA approval of vagus nerve stimulation for treating impaired upper-limb movement in stroke patients, providing a strong foundation for the current spinal cord injury research.
The current findings are particularly encouraging because they address a population with a profound unmet medical need. "The people in this study have now gained the ability to do things that are meaningful for them and impactful in their lives," Dr. Wigginton stated, underscoring the profound qualitative improvements observed.
Technological advancements have also played a pivotal role. The newest generation of the implantable CLV device, engineered by Dr. Rennaker, is approximately 50 times smaller than its predecessor from just three years ago. This miniaturization not only enhances patient comfort but also ensures compatibility with essential medical imaging techniques like MRI, CT scans, and ultrasounds, eliminating a potential barrier to continued care.
Looking ahead, the research team is preparing for a Phase 3 pivotal trial. This larger-scale study is slated to involve 70 participants across multiple leading U.S. institutions specializing in spinal cord injury care. This next phase will be critical in further validating the efficacy and safety of CLV and gathering the comprehensive data required for FDA approval.
Dr. Seth Hays, an associate professor of bioengineering and a Fellow, Eugene McDermott Distinguished Professor in the Erik Jonsson School of Engineering and Computer Science, has been a key figure in the CLV project since its inception. "Prior to this study, no person with spinal cord injury had ever received CLV," he noted. "This is the first evidence that gains can be made. Now we will set about determining how we make this optimally effective."
While acknowledging the immense progress, Dr. Hays also offered a pragmatic perspective on the path forward. "We still have a long road ahead. For many reasons — financial, regulatory or scientific — this could still die on the vine," he cautioned. "But we have positioned ourselves to succeed." This realistic outlook is crucial in managing expectations while maintaining the momentum of this promising research.
Collaborative Spirit and Patient Dedication
The success of this groundbreaking study is a testament to the collaborative efforts of numerous individuals and institutions. The research team emphasized the invaluable contributions of the dozens of people involved, including the dedicated patients who participated in the trial and TxBDC’s crucial partners at Baylor University Medical Center, Baylor Scott & White Research Institute, and Baylor Scott & White Institute for Rehabilitation.
"This has been the hardest working, most altruistic group of professionals, and that has been incredibly impactful," remarked Dr. Wigginton, highlighting the commitment and dedication of all involved.
Dr. Rennaker further emphasized the extraordinary commitment demonstrated by the patients. "Noting that even outpatient surgery is complex for those with impaired mobility, Rennaker added, ‘These patients said, ‘Put that device in me’ — that’s a huge commitment. They deserve credit for paving the path for others.’" Their willingness to undergo experimental procedures and actively participate in their rehabilitation has been instrumental in advancing this novel therapy.
The UT Dallas research team also acknowledged the contributions of several other UTD-affiliated co-authors, including Joseph Epperson, TxBDC research associate; Emmanuel Adehunoluwa, cognition and neuroscience doctoral student; Amy Porter, TxBDC director of operations; Holle Carey Gallaway, TxBDC research biomedical engineer; and David Pruitt, a doctoral graduate.
It is important to note that Dr. Kilgard has a financial interest in MicroTransponder Inc., a company that markets vagus nerve stimulation therapy for stroke. Dr. Rennaker is the founder and CEO of XNerve, the company that developed the device utilized in this study. These disclosures are standard practice in scientific reporting and underscore the translational nature of the research.
The research was supported by significant funding from the Defense Advanced Research Projects Agency (DARPA), an agency of the Department of Defense, through grant N66001-17-2-4011, as well as the Wings for Life Accelerated Translational Program. This broad-based funding reflects the national and international recognition of the potential impact of this research.
Broader Implications and Future Directions
The implications of this study extend far beyond the immediate participants. The success of CLV in individuals with spinal cord injuries, where traditional therapy alone has proven insufficient, opens up new avenues for treating a wide range of neurological conditions. The ability to significantly improve arm and hand function can restore independence, enhance quality of life, and reduce the burden of care for individuals with spinal cord injuries.
The development of smaller, more advanced implantable devices also signifies progress in neurotechnology. The fact that these devices do not interfere with essential medical imaging procedures is a critical practical consideration for long-term patient management.
As the research progresses towards a Phase 3 trial, the scientific and medical communities will be closely watching. The potential for FDA approval of CLV for spinal cord injury treatment could revolutionize rehabilitation strategies and offer a tangible path to recovery for millions worldwide. The dedication of the researchers, clinicians, and patients involved in this endeavor represents a significant leap forward in the ongoing quest to overcome the challenges posed by spinal cord injuries.
